Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Genmab
Children's Oncology Group
Essen Biotech
National Cancer Institute (NCI)
Incyte Corporation
National Cancer Institute (NCI)
OncoNano Medicine, Inc.
Wake Forest University Health Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Southern California
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
AVM Biotechnology Inc
University of Alabama at Birmingham
Novartis
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Checkpoint Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
Astex Pharmaceuticals, Inc.
University of Virginia
Celldex Therapeutics
OHSU Knight Cancer Institute
Corvus Pharmaceuticals, Inc.
Eastern Cooperative Oncology Group
Rigshospitalet, Denmark
Scripps Health
Institut Bergonié
Institut Paoli-Calmettes
Celgene
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
AbbVie
Vanderbilt-Ingram Cancer Center
City of Hope Medical Center
Daiichi Sankyo
National Institutes of Health Clinical Center (CC)
Amgen